|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Procognia Limited Signs Binding Letter of Intent with Beijing Cy-Tech for the Exclusive Marketing and Distribution of its GlycoScope™ Product in the Greater China Region
3/7/2012 7:05:21 AM
TEL-AVIV, Israel--(BUSINESS WIRE)--Procognia (TASE: PRCG), announced that, on Thursday March 1, it signed a binding letter of intent with Beijing Cy-Tech Biotech Company("Cy-Tech"), by which Cy-Tech was granted the exclusive rights to sell, distribute and market Procognia’s glycoanalysis product, the GlycoScopeTM ("the Product") in the Greater China Region (China, Hong Kong, Macao and Taiwan) ("the Territory"). In addition, Cy-Tech was awarded the exclusive right to provide its clients in the Territory with glycoanalytical services relying on knowhow and expertise that Cy-Tech will receive from the company ("the Services" and "the letter of intent"). Beyond the compensation that will be received by the company through the purchase of the Product by Cy-Tech, the company will be entitled to a certain percentage of the revenues received by Cy-Tech due to the provision of these services. Cy-Tech will be responsible for all sales and marketing activities related to the Product, and also for providing Services in the Territory, and will bear all costs associated with these services. Cy-Tech will also provide local technical support to its clients in the Territory with support from the company.
|
|
|
|
|
|
|
|
|
|
|